Ransomware in Pharma and Biotech — Threats and Drug Production Protection

Why pharma is an attractive ransomware target

Pharmaceutical companies combine three characteristics that make them ideal targets: enormous data value (formulas, clinical trials), time pressure (regulatory deadlines, cold chain), and willingness to pay (production downtime cost exceeds ransom). In 2025, BlackCat group attacked 3 European pharmaceutical companies in a single quarter. Average ransom: $4.2M. Average downtime: 18 days — which in drug manufacturing means pharmacy shortages and patient health risks.

Attack vectors targeting pharma companies

Phishing targeting regulatory affairs

Emails impersonating EMA, FDA, or CRO partners with infected attachments.

OT/SCADA system exploitation

Pharmaceutical production control systems (mixers, granulators, packaging lines) often run on outdated Windows systems without updates.

API supplier compromise

Attacks on Active Pharmaceutical Ingredient suppliers — compromising their systems provides a backdoor into the pharmaceutical network.

VPN and RDP without MFA

Remote access for lab and production equipment service technicians without multi-factor authentication is an open door.

Impact of ransomware on a pharma company

Production shutdown — locked control systems halt production lines. Drugs requiring continuous cold chain may be destroyed.

Clinical trial data loss — encryption of Phase I-III results means years of delays and hundreds of millions in losses.

GMP violation — no access to quality documentation, production logs, and validation means Good Manufacturing Practice breach.

Regulatory consequences — regulatory fines, possible manufacturing license revocation, mandatory EMA notification.

Drug shortages — halting production of critical drugs can lead to pharmacy shortages and patient health risks.

7 methods to protect pharma companies from ransomware

1. IT/OT segmentation — physical and logical separation of corporate network from production. SCADA systems in isolated zone with next-gen firewalls.

2. 3-2-1 backup with testing — 3 copies, 2 different media, 1 offline copy. Weekly restoration tests for clinical trial data.

3. EDR/XDR on all endpoints — including lab stations and computers connected to analytical equipment.

4. OT vulnerability management — regular production system scanning, patch prioritization considering maintenance windows.

5. 24/7 SOC with pharma expertise — Security Operations Center with analysts understanding pharma specifics: normal SCADA traffic patterns, validation cycles, regulatory data transfers.

6. Staff training — anti-phishing workshops adapted for pharma: recognizing fake emails from EMA, FDA, CRO partners.

7. Business continuity plan (BCP) — manual production procedures, alternative communication channels, backup supplier agreements.

Cybersecurity for Your Industry

Learn more about cybersecurity in your industry:

• Cybersecurity for Healthcare
• Cybersecurity for Manufacturing & Industry
• Cybersecurity for Pharma & Biotechnology

Best practices for implementation

Effective implementation requires several key steps:

1. Risk assessment and inventory — identify assets, threats, and vulnerabilities specific to your organization.
2. Policy development — document requirements, roles, and responsibilities.
3. Technical controls — deploy tools and configurations proportionate to identified risks.
4. Training and awareness — engage employees in protecting organizational security.
5. Monitoring and continuous improvement — regularly verify effectiveness and adapt to the evolving threat landscape.

Related topics

See also:

• NIS2 for hospitals — implementation and funding
• Security Audit Pricing Calculator
• NIS2 for hospitals — compliance